Nature Communications (Aug 2016)
Stratification and therapeutic potential of PML in metastatic breast cancer
- Natalia Martín-Martín,
- Marco Piva,
- Jelena Urosevic,
- Paula Aldaz,
- James D. Sutherland,
- Sonia Fernández-Ruiz,
- Leire Arreal,
- Verónica Torrano,
- Ana R. Cortazar,
- Evarist Planet,
- Marc Guiu,
- Nina Radosevic-Robin,
- Stephane Garcia,
- Iratxe Macías,
- Fernando Salvador,
- Giacomo Domenici,
- Oscar M. Rueda,
- Amaia Zabala-Letona,
- Amaia Arruabarrena-Aristorena,
- Patricia Zúñiga-García,
- Alfredo Caro-Maldonado,
- Lorea Valcárcel-Jiménez,
- Pilar Sánchez-Mosquera,
- Marta Varela-Rey,
- Maria Luz Martínez-Chantar,
- Juan Anguita,
- Yasir H. Ibrahim,
- Maurizio Scaltriti,
- Charles H. Lawrie,
- Ana M. Aransay,
- Juan L. Iovanna,
- Jose Baselga,
- Carlos Caldas,
- Rosa Barrio,
- Violeta Serra,
- Maria dM Vivanco,
- Ander Matheu,
- Roger R. Gomis,
- Arkaitz Carracedo
Affiliations
- Natalia Martín-Martín
- CIC bioGUNE, Bizkaia Technology Park
- Marco Piva
- CIC bioGUNE, Bizkaia Technology Park
- Jelena Urosevic
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona)
- Paula Aldaz
- Oncology Area, Biodonostia Institute
- James D. Sutherland
- CIC bioGUNE, Bizkaia Technology Park
- Sonia Fernández-Ruiz
- CIC bioGUNE, Bizkaia Technology Park
- Leire Arreal
- CIC bioGUNE, Bizkaia Technology Park
- Verónica Torrano
- CIC bioGUNE, Bizkaia Technology Park
- Ana R. Cortazar
- CIC bioGUNE, Bizkaia Technology Park
- Evarist Planet
- Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB-Barcelona)
- Marc Guiu
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona)
- Nina Radosevic-Robin
- ERTICa Research Group, University of Auvergne EA4677
- Stephane Garcia
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR 1068, CNRS UMR 7258, Aix-Marseille University and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy
- Iratxe Macías
- CIC bioGUNE, Bizkaia Technology Park
- Fernando Salvador
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona)
- Giacomo Domenici
- CIC bioGUNE, Bizkaia Technology Park
- Oscar M. Rueda
- Cancer Research UK Cambridge Institute, University of Cambridge
- Amaia Zabala-Letona
- CIC bioGUNE, Bizkaia Technology Park
- Amaia Arruabarrena-Aristorena
- CIC bioGUNE, Bizkaia Technology Park
- Patricia Zúñiga-García
- CIC bioGUNE, Bizkaia Technology Park
- Alfredo Caro-Maldonado
- CIC bioGUNE, Bizkaia Technology Park
- Lorea Valcárcel-Jiménez
- CIC bioGUNE, Bizkaia Technology Park
- Pilar Sánchez-Mosquera
- CIC bioGUNE, Bizkaia Technology Park
- Marta Varela-Rey
- CIC bioGUNE, Bizkaia Technology Park
- Maria Luz Martínez-Chantar
- CIC bioGUNE, Bizkaia Technology Park
- Juan Anguita
- CIC bioGUNE, Bizkaia Technology Park
- Yasir H. Ibrahim
- Experimental Therapeutics Group, Vall d'Hebron University Hospital
- Maurizio Scaltriti
- Department of Pathology, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- Charles H. Lawrie
- Oncology Area, Biodonostia Institute
- Ana M. Aransay
- CIC bioGUNE, Bizkaia Technology Park
- Juan L. Iovanna
- Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR 1068, CNRS UMR 7258, Aix-Marseille University and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy
- Jose Baselga
- Department of Medicine, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- Carlos Caldas
- Cancer Research UK Cambridge Institute, University of Cambridge
- Rosa Barrio
- CIC bioGUNE, Bizkaia Technology Park
- Violeta Serra
- Experimental Therapeutics Group, Vall d'Hebron University Hospital
- Maria dM Vivanco
- CIC bioGUNE, Bizkaia Technology Park
- Ander Matheu
- Oncology Area, Biodonostia Institute
- Roger R. Gomis
- Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona)
- Arkaitz Carracedo
- CIC bioGUNE, Bizkaia Technology Park
- DOI
- https://doi.org/10.1038/ncomms12595
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 13
Abstract
Targeting PML in acute promyelocytic leukaemia has changed the outcome of patients with this disease. Here, the authors demonstrated that PML is also a potential therapeutic target in breast cancer where it specifically regulates cancer initiating cells and tumour progression through the transcriptional regulation of SOX9.
